Key facts
- This page summarizes Peter A. Thompson's Form 4 filing for Edgewise Therapeutics, Inc. (EWTX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 04 Apr 2025, 19:42.
Peter A. Thompson - 03 Apr 2025 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- EWTX
- Reported as of
- 03 Apr 2025
- Net transaction value
- +$10,000,000
- SEC form
- 4
- Accepted by SEC
- 04 Apr 2025, 19:42:30 UTC
- Prior SEC filing
- 10 Feb 2025
- Next SEC filing
- 16 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Peter A. Thompson
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Peter A. Thompson filed Form 4 for Edgewise Therapeutics, Inc. (EWTX) on 04 Apr 2025.
Change
- Previous filing in this sequence was filed on 10 Feb 2025.
- Current net transaction value: +$10,000,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EWTX
transaction
Common Stock
Purchase
- Transaction value
- $7,499,995
- Shares
- +372,578
- Change %
- +2.6%
- Price
- $20.13
- Shares after
- 14,809,075
- Date
- 03 Apr 2025
- Ownership
- See footnotes
- Footnotes
- F1, F2, F4
EWTX
transaction
Common Stock
Purchase
- Transaction value
- $2,500,005
- Shares
- +124,193
- Change %
- +39%
- Price
- $20.13
- Shares after
- 443,792
- Date
- 03 Apr 2025
- Ownership
- See footnotes
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
These shares of the Issuer's common stock were purchased in an underwritten public offering.
Footnote F2
These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI VI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI.
Footnote F3
These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund and OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by Genesis Master Fund.
Footnote F4
Each of the Reporting Person, OrbiMed Advisors, GP VI, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his or its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.